Medicines Discovery Catapult

At MDC, we have a range of Mass Spectrometry Imaging (MSI) specialisms that we can help the drug discovery community with: ☑️ Blood brain barrier penetration of label-free drugs and their metabolites in frozen tissue sections ☑️ Measurement of downstream therapeutic response and biomarker discovery ☑️ Enzymatic digestion and analysis of proteins in FFPE tissue sections ☑️ Drug and metabolite distribution in target and off-target tissues ☑️ Skin penetration studies of complex medicines in a variety of skin models 📩 Speak to us, we can help support you with your next project: https://hubs.li/Q03Bxnkp0 #MassSpectrometryImaging #MSI #DrugDiscovery

Chemical Protein Stability Assay (CPSA), can be applied at every step of the #DrugDiscovery process, regardless of which cellular matrix you choose. We can generate biologically relevant data that helps you identify and prioritise drug candidates faster. 🧬 👉 Explore our poster: MDC Chemical Protein Stability Assay (CPSA) a novel target engagement approach. Full page view: https://hubs.li/Q03z-kvZ0 #DrugDelivery #ChemicalProteinStabilityAssay

We recently shared that, NI-based SMEs, SignaCorand KlasTherapeutics have secured £1M from Innovate UK's Launchpad fund. We are pleased to support their groundbreaking work in heart disease and skin cancer with our expertise, technology and commercial insights: https://hubs.li/Q03z-jYw0 #LifeSciences #Innovation

🫁 Today is NTM Awareness Day, an important opportunity to raise awareness about nontuberculous mycobacterial disease (NTM). This condition continues to impact people with Cystic Fibrosis and others living with chronic lung infections. NTM infections are notoriously difficult to manage, with many affected facing significant challenges with the current, limited treatment options. More innovation is urgently needed to help drive the pipeline. Through the Collaborative Discovery Programme, the CF AMR Syndicate is privileged to support BioVersys, an SME tackling this urgent unmet need by advancing its asset targeting NTM. Hear our interview with the company’s CEO, Dr Marc Gitzinger, about their work and recent exciting developments. More from Marc tomorrow in part 2. Cystic Fibrosis Trust | Medicines Discovery Catapult | LifeArc BioVersys AG, Shionogi Europe, COPD Foundation, Bronchiectasis and NTM Association, NTM Network UK, Cystic Fibrosis Foundation #NTMAwarenessDay2025 #NTMLungDisease #CysticFibrosis #RareDiseaseAwareness

Have you met the MDC team at events this year? If you would like to see upcoming events, check the resources section of our website. Get in touch if you would like to arrange a meeting to discuss how we can support your drug discovery research. 🔗 in comments. #DrugDiscovery

Meet MDC’s Head of R&D Consulting, Johnny Habchi Johnny is a leader in life sciences R&D with 15  years of experience in academia, biotech, and consultancy. His passion lies in bridging cutting-edge science with business strategy to translate scientific innovations into therapeutic solutions. #DrugDiscovery #LifeSciences

MDC's national total-body PET imaging programme, NPIP recently released the below paper, outlining how initiative will support the UK radiopharmaceutical community to establish a collaborative approach to regulation and safe patient access: 📓 Securing the Future of Radiopharmaceuticals: Introducing the Trusted Advisor Group Access here: https://hubs.li/Q03zhMyQ0

🎯 As radiopharmaceuticals become a central component in treating metastatic castration-resistant #prostatecancer the need for preclinical models that accurately reflect human disease is critical. Champions Oncology, Inc. and MDC address this gap by working together to provide an advanced platform that integrates patient-derived xenograft (PDX) models with radiochemistry capabilities: https://hubs.li/Q03y22Fw0 #mCRPC #DrugDiscovery

Chemical Protein Stability Assay (CPSA), is MDC’s in-house developed solution for assessing cellular protein-ligand or protein-drug binding. 💊 Our patented assay applies to a range of cellular protein targets and can be configured using a range of protein detection technologies, depending on the throughput required for analysis. Read more: https://hubs.li/Q03y2bJf0 #DrugDiscovery #CellularScience #LifeScience

Applications for KQ Labs Cohort 8 are now open, inviting early-stage data-driven health founders to join one of their upcoming online Discovery Q&A sessions. 📅 Upcoming session dates: • Tuesday 22 July, 10:00 – 11:00 BST • Tuesday 5 August, 10:00 – 11:00 BST • Tuesday 19 August, 12:00 – 13:00 BST More details: https://hubs.li/Q03y0j-B0 #KQLabs #DrugDiscovery